Abstract:Christoph Sinning 1,2^ 1 Department of Cardiology, University Heart & Vascular Center Hamburg, Hamburg, Germany; 2 German Centre of Cardiovascular Research (DZHK), Partner Site Hamburg/Kiel/Lübeck, Hamburg/Kiel/Lübeck, Germany ^ ORCID: 0000-0002-7331-8840. Comment on: Fischer U, Koga M, Strbian D, et al . Early versus Later Anticoagulation for Stroke with Atrial Fibrillation. N Engl J Med 2023;388:2411-21. Keywords: Stroke; anticoagulation; imaging; outcome Submitted Sep 25, 2023. Accepted for publication Dec 18, 2023. Published online Jan 24, 2024. doi: 10.21037/apm-23-555 The start of therapeutic anticoagulation following stroke in patients with AF is an important question as a late onset might increase the risk of complications like recurrent ischemic stroke in patients (1,2). In patients with acute ischemic stroke and AF, early start of anticoagulation is associated with less recurrent stroke but with the risk of hemorrhagic transformation of the infarcted area (3). In the literature a later onset of 12 days is described in patients with hemorrhagic transformation following ischemic stroke in AF patients (3). The current guidelines recommend a start of therapeutic anticoagulation in the time frame of 7 to 14 days following the stroke (1,2). Early initiation of anticoagulation is not without reported risk, as one study showed that patients started on direct oral anticoagulants (DOACs) within 2 days of acute stroke had a composite rate of recurrence and major bleeding of 12.4%, and composite rates were 2.1% for those started on DOACs between 3 and 14 days, 9.1% for those started on DOACs >14 days after acute stroke (4). Thus, it still remains to elucidate when the best time to initiate treatment in patients with acute stroke is directly following the event or at different time in the first 4 days. However, these data have limitations as the study was observational and further patients were allowed to receive low molecular weight heparin before DOAC. In addition, the study had multiple selection bias to only include patients which were deemed at a low risk for hemorrhage or with mild stroke regarding impairment or small size (5). The most often variable to grade stroke severity is the National Institutes of Health Stroke Scale (NIHSS) which increases due to the documented impairment with an increase of the score (6,7). In the recent years investigators did collect data of magnetic resonance imaging (MRI) in a multicenter approach to predict infarct size and location as the implications are important for decision-making and to establish prognosis in patients with acute stroke (8,9). As of current due to progressive establishment of neural networks in research and science prediction of the final infarct size can be established with the baseline MRI (8,9). In the context of this background multiple studies are currently prospectively investigating if an early start of therapeutic anticoagulation might be non-inferior to the recommended approach with OPTIMAS and the completed ELAN and TIMING studies (10-12). In general, DOACs should be preferred, if possible, in patients with AF (13,14). Recent data from the large, randomised, international ELAN trial showed that early treatment was associated with an estimated 2.8% points lower and 0.5% points higher incidence of the composite of stroke, systemic embolism, bleeding or death at 30 days compared with later treatment (11). The approach to defining treatment initiation in this trial was based on imaging with the following definitions: an infarct of 1.5 cm or less was defined as small; an infarct in the distribution of a cortical superficial branch of the middle, anterior or posterior cerebral artery was defined as moderate; and larger infarcts in the distribution of these arteries or a brainstem or cerebellar infarct larger than 1.5 cm were defined as large (11). According to this imaging-based definition of stroke size the anticoagulation was started in the ELAN study in the first 48 hours in minor and moderate stroke and on day 6 to 7 in a major stroke (11). The treatment approach with early start of DOAC treatment in the first 48 hours in case of minor or moderate stroke is differing from similar designed studies (10,12) and could be an important approach to individualize the treatment in patients. In comparison to the imaging-based scheme in ELAN the TIMING study did randomize the patient in the first 72 hours with an allocation to early start of DOACs with ≤4 days or a delayed start with ≥5 to 10 days (12). The still ongoing OPTIMAS study which investigates if start of DOACs within 4 days of stroke onset is as effective or better than delayed initiation 7 to 14 days from the onset event did not report the outcomes yet (10). Thus, the time to start anticoagulation is still different in ELAN which did us an imag -Abstract Truncated-

Abstract TP197: Early Direct Oral Anticoagulants Therapy After Ischemic Stroke In Patients With And Without Atrial Fibrillation:A Pooled Analysis Of Five Studies

Abstract Number ‐ 49: Risk of HT with Early DOACs after Acute Ischemic Stroke: A Pooled Analysis

Risk of hemorrhagic transformation with early use of direct oral anticoagulants after acute ischemic stroke: A pooled analysis of prospective studies and randomized trials

Abstract WP144: Early Initiation of Anticoagulation is Safe After Ischemic Stroke With Atrial Fibrillation, Meta-Analysis and Systemic Review

Direct oral anticoagulants versus vitamin K antagonists after recent ischemic stroke in patients with atrial fibrillation

Early Versus Late Initiation of Direct Oral Anticoagulants After Ischemic Stroke in People With Atrial Fibrillation and Hemorrhagic Transformation: Prespecified Subanalysis of the Randomized Controlled ELAN Trial

Time to benefit and harm of direct oral anticoagulants in device-detected atrial fibrillation: A pooled analysis of the NOAH-AFNET 6 and ARTESiA trials

Abstract 66: Optimal Delay Time to Initiate Anticoagulation After Ischemic Stroke in Atrial Fibrillation: Primary Results of the START Trial

Timing of oral anticoagulants initiation for atrial fibrillation after acute ischemic stroke: A systematic review and meta-analysis

Assessing mortality and safety of IV thrombolysis in ischemic stroke patients on direct oral anticoagulants (DOACs): A systematic review and meta-analysis

Abstract 25: Intravenous Thrombolysis for Acute Ischemic Stroke in Patients With Recent Direct Oral Anticoagulant Use: A Systematic Review and Meta-Analysis

Abstract WP19: Is Direct Oral Anticoagulant More Effective Than Warfarin to Reduce Size of Left Atrial Thrombus in Stroke Patients?

Abstract WP11: The Safety of Emergent Anticoagulation in Acute Ischemic Stroke in Non-Atrial Fibrillation Indications: A Retrospective Analysis

Direct oral anticoagulants for stroke prevention in patients with device-detected atrial fibrillation: assessing net clinical benefit

Anticoagulation Usage and Thrombolytic Therapy in Subjects with Atrial Fibrillation Associated Ischaemic Stroke.

Changes in anticoagulation practice in subjects admitted with stroke associated with atrial fibrillation, following introduction of direct oral anticoagulants over 2013-2021

Anticoagulation Therapy Timing in patients with Atrial Fibrillation after Acute and Chronic Subdural Haematoma (ATTAACH): a pilot randomised controlled trial

Cerebral haemorrhage in the patient with atrial fibrillation: do we employ the direct oral anticoagulants without waiting too long?

Early vs Late Anticoagulation in Acute Ischemic Stroke with Indications Outside Atrial Fibrillation

Abstract WP12: Early or Later Anticoagulation in Post-Stroke Patients With Atrial Fibrillation: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

Early start of anticoagulation in stroke—timing is essential!